Parkinson's Disease and <scp>Post–COVID</scp>‐19 Syndrome: The Parkinson's <scp>Long‐COVID</scp> Spectrum

Leta, Valentina; Rodríguez-Violante, Mayela; Abundes, A.; Rukavina, Katarina; Teo, James; Falup‐Pecurariu, Cristian; Irincu, Laura; Rota, Silvia; Bhidayasiri, Roongroj; Storch, Alexander; Odin, Per; Antonini, Angelo; Chaudhuri, K. Ray

doi:10.1002/mds.28622

Cited by 59 publications

(30 citation statements)

References 6 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These include post-traumatic stress disorder, Guillain-Barré syndrome, depression, and cognitive impairment [50]. The worsening of motor function (51.9%) and an increased levodopa daily dose requirement (48.2%), followed by fatigue (40.7%) and cognitive and sleep disturbances (22.2% each), were present in 23 (85.2%) of 27 patients with Parkinson's disease and COVID-19, who developed post-COVID syndrome [51].…”

Section: Clinical Manifestationsmentioning

confidence: 99%

Post-COVID Syndrome: An Insight on Its Pathogenesis

2021

View full text Add to dashboard Cite

Post-COVID syndrome is increasingly recognized as a new clinical entity in the context of SARS-CoV-2 infection. Symptoms persisting for more than three weeks after the diagnosis of COVID-19 characterize the post-COVID syndrome. Its incidence ranges from 10% to 35%, however, rates as high as 85% have been reported among patients with a history of hospitalization. Currently, there is no consensus on the classification of post-COVID syndrome. We reviewed the published information on post-COVID syndrome, putting emphasis on its pathogenesis. The pathogenesis of post-COVID syndrome is multi-factorial and more than one mechanism may be implicated in several clinical manifestations. Prolonged inflammation has a key role in its pathogenesis and may account for some neurological complications, cognitive dysfunction, and several other symptoms. A multisystem inflammatory syndrome in adults (MIS-A) of all ages has been also described recently, similarly to multisystem inflammatory syndrome in children (MIS-C). The post-infectious inflammatory pathogenetic mechanism of MIS-A is supported by the fact that its diagnosis is established through serology in up to one third of cases. Other pathogenetic mechanisms that are implicated in post-COVID syndrome include immune-mediated vascular dysfunction, thromboembolism, and nervous system dysfunction. Although the current data are indicating that the overwhelming majority of patients with post-COVID syndrome have a good prognosis, registries to actively follow them are needed in order to define the full clinical spectrum and its long-term outcome. A consensus-based classification of post-COVID syndrome is essential to guide clinical, diagnostic, and therapeutic management. Further research is also imperative to elucidate the pathogenesis of post-COVID syndrome.

show abstract

Section: Clinical Manifestationsmentioning

confidence: 99%

Post-COVID Syndrome: An Insight on Its Pathogenesis

2021

View full text Add to dashboard Cite

show abstract

“…Unprecedented restrictions have been implemented to control the viral spread, including a complete lockdown of quarantine isolation in certain countries including Italy [ 1 ]. Concerns about the severe restrictions in mobility and the subsequent sedentary lifestyle have been raised when dealing with chronic neurological conditions, such as Parkinson’s disease (PD) [ 2 – 5 ]. Falls are more common (up to 40–70% per year) in advanced PD and their frequency and severity increase with physical inactivity [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of social and mobility restrictions in Parkinson’s disease during COVID-19 lockdown

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background The consequences of strict COVID-19 mobility restrictions on motor/non-motor features in Parkinson’s disease (PD) have not been systematically studied but worse mobility and quality of life have been reported. To elucidate this question, 12 mild to moderate PD patients were assessed in March 2020 before and after two months of isolation as part of a clinical study that had to be interrupted due to the pandemic and the implementation of COVID19 mobility restrictions. Methods Twelve patients were systematically evaluated before and after the lockdown period as part of a larger cohort that previously underwent thermal water rehabilitation. Clinical outcomes were the Body Mass index, the Mini-Balance Evaluation Systems Test, the MDS-Unified Parkinson’s Disease Rating Scale part III, the 6 Minute Walking Test and the New Freezing of Gait Questionnaire. Global cognition was evaluated with the Montreal Cognitive Assessment scale. The impact of COVID-19 restrictions on quality of life and functional independence was evaluated with The Parkinson’s disease Quality of life (PDQ-39), the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living questionnaires (IADL) and the Parkinson’s disease cognitive functional rating scales (PD-CFRS). Results After two months of isolation the Mini-BESTest score worsened (p=0.005), and four patients reported one or more falls during the lockdown. BMI increased (p=0.031) while the remaining clinical variables including quality of life did not change. Conclusion We observed moderate worsening at Mini-BESTest, greater risk of falls and increased body weight as consequence of prolonged immobility. We believe negative effects were partially softened since patients were in contact with our multidisciplinary team during the lockdown and had previously received training to respond to the needs of this emergency isolation. These findings highligh the importnace of patient-centered interventions in PD management.

show abstract

“…COVID-19 may also longitudinally impact patients with Parkinson’s disease, although the evidence is limited. Leta and colleagues observed “post-COVID syndrome” (defined as symptoms persisting beyond 12 weeks) in 27 patients with Parkinson’s, noting worsening motor function (51.9%) and increased levodopa requirements (48.2%) [ 109 ]. Finally, there have been a number of Guillain–Barre (GBS) cases associated with COVID-19, with one study identifying over 70 cases [ 19 , 110 ], although a causal link has not been established.…”

Section: Main Textmentioning

confidence: 99%

Neurological sequelae of COVID-19: a review

Peterson

Sarangi

Bangash

2021

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background The COVID-19 pandemic has produced a myriad of challenges, including identifying and treating neurological sequelae. Main body COVID-19 can cause olfactory and respiratory dysfunction with average recovery within 1 month and a minority of patients experiencing symptoms at 8-month follow-up. Headaches are also very common (up to 93%) amongst patients with persistent COVID-19 symptoms. COVID-19 illness may also affect cognition, although results are mixed. Conclusion While many studies have focused on acute COVID-19 symptoms, more longitudinal studies will need to assess the neurological sequelae of the disease. Furthermore, care must be taken when attributing sequelae to COVID-19 illness and not an unrelated cause. Finally, there is concern that COVID-19 may be associated with secondary illnesses, such as Guillain–Barre, and may even contribute to the development of diseases, such as Alzheimer’s.

show abstract

Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum

Cited by 59 publications

References 6 publications

Post-COVID Syndrome: An Insight on Its Pathogenesis

Post-COVID Syndrome: An Insight on Its Pathogenesis

Impact of social and mobility restrictions in Parkinson’s disease during COVID-19 lockdown

Neurological sequelae of COVID-19: a review

Contact Info

Product

Resources

About